

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: **HITTINGER et al.** Examiner: SEAMAN, D Margaret M

Application No.: **10/773,806** Art Unit: 1625

Filed: **February 6, 2004**

Title: **CHEMICAL DERIVATIVES AS ANTITELOMERASE AGENTS WHICH  
BIND SPECIFICALLY TO THE G-QUADRUPLEX DNA STRUCTURES  
AND THEIR APPLICATION AS A SPECIFIC ANTICANCER AGENT**

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. 1.56, 1.97 AND 1.98**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

A concise explanation of the relevance of some or all of the items listed on the attached PTO-1449 (modified) is as follows:

The Lavelle, Blasco, Morin, Kim, and Perry references and the abstract of the Singh article were cited by a USPTO Examiner on August 13, 2007 in copending U.S. Patent Application No. 10/658,394.

This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or any additional fees required by this paper or credit any overpayment to Account No. **18-1982**.

Respectfully submitted,

September 18, 2007

Date

sanofi-aventis U.S. LLC  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (610) 889-8995  
Telefax (908) 231-2626

Kelly L. Bender

Kelly L. Bender, Reg. No. 52,610  
Attorney for Applicant

Sanofi-Aventis Docket No. FRAV2003/0004 US NP

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/773,806		
		Filing Date	02-06-2004		
		First Named Inventor	HITTINGER		
		Group Art Unit	1625		
		Examiner Name	SEAMAN, D. Margaret M.		
Sheet	1	of	1	Attorney Docket Number	FRAV2003/0004 - US - NP

<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BLASCO et al, Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA, Cell, 1997, 91, pp. 25-34	
		KIM et al, Specific Association of Human Telomerase Activity with Immortal Cells and Cancer, Science, 1994, 266, pp.2011-2015	
		LAVELLE, American Association for Cancer Research 1998: Promises and Prospects for the Next Century, Expert Opinion on Investigational Drugs, 1998, 7(6), pp. 1015-1021	
		MORIN, Is Telomerase a Universal Cancer Target?, Journal of the National Cancer Institute, 1995, 87 (12), pp.859-861	
		PERRY et al, Recent Advances in the Development of Telomerase Inhibitors for the Treatment of Cancer, Exp. Opin. Invest. Drugs (1999) 8(12), pp.1981-2008	
		SINGH et al, Antimalarials. "Distal" Hydrazine Derivatives of 7-Chloroquinoline, J. Med. Chem., 1971, 14(6), pp. 532-535	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.